Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aptevo Therapeutics Inc

Current price
0.42 USD +0.0086 USD (+2.11%)
Last closed 0.43 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 173 273 USD
Yield for 12 month -63.54 %
21.11.2021 - 28.11.2021

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Address: 2401 4th Avenue, Seattle, WA, United States, 98121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

13.75 USD

P/E ratio

Dividend Yield

Current Year

Last Year

+3 114 000 USD

Current Quarter

Last Quarter

+902 000 USD

Current Year

-567 000 USD

Last Year

+2 213 000 USD

Current Quarter

-106 000 USD

Last Quarter

+786 000 USD

Key Figures APVO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -27 610 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -66.79 %
PEG Ratio
Return On Equity TTM -186.05 %
Wall Street Target Price 13.75 USD
Revenue TTM
Book Value 9.06 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100 %
Dividend Yield
Gross Profit TTM 3 114 000 USD
Earnings per share -94.4 USD
Diluted Eps TTM -94.4 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics APVO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History APVO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:44
Payout Ratio
Last Split Date 06.03.2024
Dividend Date 27.03.2020

Stock Valuation APVO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 3.9448
Enterprise Value Revenue 0.1222
Price Sales TTM 1.6074
Enterprise Value EBITDA 0.3863
Price Book MRQ 0.0466

Financials APVO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators APVO

For 52 weeks

0.28 USD 49.28 USD
50 Day MA 0.62 USD
Shares Short Prior Month 21 105
200 Day MA 5.57 USD
Short Ratio 1.32
Shares Short 348 711
Short Percent 8.55 %

Dynamics of changes in the value of assets



12.82 GBX Enquest Plc -0 (-0.62%)
Detailed analytics


0.0070 AUD BMG Resources Ltd +0 (+0%)
Detailed analytics


0.21 EUR Verianos SE 0 (0%)
Detailed analytics


0.029 AUD Remsense Technologies Ltd +0 (+0%)
Detailed analytics


0.0011 USD Peak Minerals Limited 0 (0%)
Detailed analytics